Literature DB >> 22925525

Aqueous calcium sulphate as bone graft for voids following open curettage of bone tumours.

Luke James Johnson1, Mark Clayer.   

Abstract

INTRODUCTION: Reported strategies for void filling in bone include autograft, allograft, synthetic bone substitutes or various combinations of these materials, but poor response rates and donor morbidity have created a desire to find a better option. Calcium sulphate as a stand-alone graft material reconstruct bone following curettage has not been previously reported. The purpose of this study was to assess the efficacy and radiological quality of healing, the time to healing, the functional outcomes and the complications following curettage and grafting using an injectable aqueous calcium sulphate (BonePlast; Biomet, Warsaw, IN, USA) as the sole grafting strategy.
METHODS: The procedure of curettage and grafting with an aqueous solution of calcium sulphate was undertaken. The patients were regularly reviewed clinically and radiologically for a minimum of 12 months (range: 12-85 months). Forty-six procedures in 46 patients were reviewed. Radiological outcomes of healing were established and functional outcomes were obtained from each patient at annual follow-up review.
RESULTS: A complete response was seen in 38 patients (83%) at a median of 6 months following the procedure (range: 1-24 months). Seven patients (15%) displayed only a partial response after a median of 13 months post-surgery (range: 12-53 months). There was one non-response to treatment (2%) after 40 months of follow-up. The mean functional score was 99%. DISCUSSION: Aqueous calcium sulphate as a sole grafting agent for void management after curettage simplifies current treatment practices and displays good bone reconstruction in a comparatively short time frame, with excellent functional results and acceptable complication rates in the setting of tumour surgery.
© 2012 The Authors. ANZ Journal of Surgery © 2012 Royal Australasian College of Surgeons.

Entities:  

Keywords:  bone graft; bone tumours; calcium sulphate; curettage

Mesh:

Substances:

Year:  2012        PMID: 22925525     DOI: 10.1111/j.1445-2197.2012.06175.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  6 in total

1.  Reply to the Letter to the Editor: Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX ®.

Authors:  Joerg Friesenbichler; Werner Maurer-Ertl; Patrick Sadoghi; Ulrike Pirker-Fruehauf; Koppany Bodo; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2013-12-10       Impact factor: 4.176

2.  Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®.

Authors:  Joerg Friesenbichler; Werner Maurer-Ertl; Patrick Sadoghi; Ulrike Pirker-Fruehauf; Koppany Bodo; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

3.  Lytic Complications after Skull Reconstruction Using GeneX®.

Authors:  Jin-Hack Park; Sang-Jun Suh; Yoon-Soo Lee; Jeong-Ho Lee; Kee-Young Ryu; Dong-Gee Kang
Journal:  Korean J Neurotrauma       Date:  2015-10-31

4.  Clinical experience with the artificial bone graft substitute Calcibon used following curettage of benign and low-grade malignant bone tumors.

Authors:  Joerg Friesenbichler; Werner Maurer-Ertl; Marko Bergovec; Lukas A Holzer; Kathrin Ogris; Lukas Leitner; Andreas Leithner
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

5.  Is Use of Bone Cement for Treatment of Second Metatarsal Stress Fractures Safe? A Case Report.

Authors:  Haley M McKissack; Jun Kit He; Tyler P Montgomery; John T Wilson; Aaradhana J Jha; Leonardo V Moraes; Ashish Shah
Journal:  Cureus       Date:  2018-10-09

6.  The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone.

Authors:  Wolfram Weschenfelder; John M Abrahams; Luke J Johnson
Journal:  World J Surg Oncol       Date:  2021-02-02       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.